February 2010 Volume 7 Number 2
Visit Nature Reviews Clinical Oncology online to browse the
journal.
Now available at
http://links.ealert.nature.com/ctt?kn=36&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Clinical Oncology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=46&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=72&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
*********************************************************************
Nature Reviews Clinical Oncology Impact Factor: 9.113*
(*Journal Citation Reports, Thomson, 2008)
*********************************************************************
=========================== ADVERTISEMENT ===========================
British Journal of Cancer presents:
NEW SUPPLEMENT
Diagnosing Cancer Earlier: Evidence for a National Awareness and Early
Diagnosis Initiative
Late diagnosis is generally accepted as a key factor in poor cancer
survival rates. Researchers from many disciplines here set out the
evidence and the enormous potential benefits of further identifying
and tackling the root causes.
View the supplement at:
http://links.ealert.nature.com/ctt?kn=58&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
=====================================================================
----------------------
EDITORIAL
----------------------
Breast cancer screening and mortality
Vincent T. DeVita, Jr
p65 | doi:10.1038/nrclinonc.2009.232
http://links.ealert.nature.com/ctt?kn=25&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
----------------------
RESEARCH HIGHLIGHTS
----------------------
Hematology: Nilotinib as first-line therapy for Ph+ CML
p67 | doi:10.1038/nrclinonc.2009.228
http://links.ealert.nature.com/ctt?kn=29&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Genetics: Four-gene signature predicts survival in NSCLC
p68 | doi:10.1038/nrclinonc.2009.225
http://links.ealert.nature.com/ctt?kn=11&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
S-100B predicts survival in melanoma
p68 | doi:10.1038/nrclinonc.2009.226
http://links.ealert.nature.com/ctt?kn=15&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Medical oncology: Carcinoembryonic antigen mRNA expression-a marker for
early pancreatic cancer recurrence?
p69 | doi:10.1038/nrclinonc.2009.227
http://links.ealert.nature.com/ctt?kn=18&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Chemotherapy: Satraplatin delays progression in prostate cancer
p69 | doi:10.1038/nrclinonc.2009.230
http://links.ealert.nature.com/ctt?kn=90&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Immunotherapy: Predicting HSCT outcome in patients with neuroblastoma
p70 | doi:10.1038/nrclinonc.2009.224
http://links.ealert.nature.com/ctt?kn=93&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Hematology: Promising new agent for B-cell lymphoma
p70 | doi:10.1038/nrclinonc.2009.229
http://links.ealert.nature.com/ctt?kn=82&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Targeted therapies: Optimal first-line therapy for NSCLC with EGFR
mutations
Joel W. Neal and Lecia V. Sequist
p71 | doi:10.1038/nrclinonc.2009.191
Activating mutations in EGFR are characteristic of patients with lung
cancer who have high sensitivity to EGFR tyrosine kinase inhibitors,
such as gefitinib and erlotinib. The randomized IPASS study by Mok and
colleagues confirmed that patients with EGFR mutations have a higher
response rate, longer progression-free survival and improved quality
of life when treated with first-line gefinitib instead of chemotherapy.
http://links.ealert.nature.com/ctt?kn=85&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Surgical oncology: Why biopsying metastatic breast cancer should be
routine
Anand Sharma, Tim Crook, Alastair Thompson and Carlo Palmieri
p72 | doi:10.1038/nrclinonc.2009.222
Currently, acquisition of tissue from presumed metastatic deposits in
breast cancer is not routine. Instead therapeutic decisions in this
setting are based on the features of the tumor at initial diagnosis.
As biopsies are diagnostic and changes can occur between the primary
and the secondary tumors, the routine biopsy of suspected metastatic
deposits needs to be considered. Such biopsies will also be key to
translational research, which will underpin future therapeutic advances.
http://links.ealert.nature.com/ctt?kn=86&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Chemotherapy: Cisplatin combinations in cervical cancer-which is best?
David O. Holtz and Charles J. Dunton
p74 | doi:10.1038/nrclinonc.2009.220
We reviewed the results of the Gynecological Oncology Group 204 (GOG-204)
randomized phase III trial, which investigated four cisplatin combination
chemotherapy regimens for the treatment of patients with recurrent or
metastatic cervical carcinoma. As the overall survival was similar
between all arms, treatment recommendations need to be tailored based
on toxic effects.
http://links.ealert.nature.com/ctt?kn=10&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Medical oncology: Treatment and management of malignant gliomas
Deric M. Park, Sith Sathornsumetee and Jeremy N. Rich
p75 | doi:10.1038/nrclinonc.2009.221
The considerable progress made in the field of clinical neuro-oncology
and the understanding of brain tumor biology is generating cautious
optimism. Treatment options for patients with glioblastoma multiforme
(GBM), the most common form of malignant gliomas, now include
anti-angiogenic therapy after failure of standard multi-modality
treatments. Furthermore, scientific advancements are providing new
insights into disease pathogenesis and point to novel therapeutic
approaches for a disease that traditionally lacked treatment options.
http://links.ealert.nature.com/ctt?kn=5&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Chemotherapy: Continued lack of progress in SCLC
Janakiraman Subramanian and Ramaswamy Govindan
p77 | doi:10.1038/nrclinonc.2009.223
Chemotherapy options for patients with extensive-stage small-cell lung
cancer (SCLC) are limited. A recent phase III trial assessed the combination
of carboplatin and pemetrexed but this regimen produced inferior survival
results compared with the standard carboplatin and etoposide regimen. The
combination of carboplatin and etoposide remains the standard first-line
chemotherapy option for the treatment of patients with extensive-stage SCLC.
http://links.ealert.nature.com/ctt?kn=7&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Chemotherapy: Dose-dense treatment for triple-negative breast cancer
Eitan Amir, Alberto Ocana, Orit Freedman, Mark Clemons and Bostjan Seruga
p79 | doi:10.1038/nrclinonc.2009.231
Dose-dense chemotherapy has been proposed to improve breast cancer
outcome due to its ability to prevent cancer cell repopulation; however,
little is known about which patients benefit most from such scheduling.
A pooled analysis of studies assessing dose-dense adjuvant chemotherapy
has shown that most of the therapeutic benefit derived from dose-dense
scheduling arises in patients with node-positive, triple-negative disease.
http://links.ealert.nature.com/ctt?kn=34&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Targeted therapies: Tailored treatment for ovarian cancer: are we there yet?
Cristiana Sessa and Gianluca Del Conte
p80 | doi:10.1038/nrclinonc.2009.233
First-line platinum and taxane chemotherapy improves the prognosis of
patients with epithelial ovarian cancer (EOC), however, about 80% of
patients relapse and long-term survival is poor. The development of drug
resistance is the main cause of treatment failure; therefore, the
identification of new compounds that interfere with tumor growth and
survival is a priority.
http://links.ealert.nature.com/ctt?kn=22&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
The role of SRC-3 in human breast cancer
Ondrej Gojis, Bharath Rudraraju, Mihir Gudi, Katy Hogben, Sami Sousha,
Charles R. Coombes, Susan Cleator and Carlo Palmieri
Published online: 22 December 2009
p83 | doi:10.1038/nrclinonc.2009.219
Members of the nuclear receptor superfamily of transcription factors have
been implicated in a broad range of normal physiological and disease
processes. There is evidence in support of the involvement of these
co-regulators in breast cancer progression. The authors review the role
of steroid receptor coactivator-3, which is frequently amplified in breast
cancer, and discuss its role in breast cancer risk, outcome and response
to endocrine therapy in patients with breast cancer.
Abstract: http://links.ealert.nature.com/ctt?kn=65&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=44&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Genomic markers for decision making: what is preventing us from using markers?
Vicky M. Coyle and Patrick G. Johnston
Published online: 15 December 2009
p90 | doi:10.1038/nrclinonc.2009.214
There has been extensive research evaluating the clinical usefulness of
genomic biomarkers. High-throughput genomic technologies have revolutionized
genomic research but challenges in biomarker assessment include clinical
study design, reproducibility and interpretation of results. This Review
explores these challenges, focusing on microarray-based gene-expression
profiling, and highlights some common failings in study design that have
impacted on the clinical use of putative genomic markers.
Abstract: http://links.ealert.nature.com/ctt?kn=66&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=39&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Molecular predictors of response to trastuzumab and lapatinib in breast
cancer
Francisco J. Esteva, Dihua Yu, Mien-Chie Hung and Gabriel N. Hortobagyi
Published online: 22 December 2009
p98 | doi:10.1038/nrclinonc.2009.216
Trastuzumab and lapatinib improve survival in patients with HER2-positive
breast cancer and there is great interest in developing diagnostic tests
that predict which patients are more likely to benefit from specific
HER2-directed therapies. This article discusses the predictive role of
HER2 mRNA, predictive markers for response to therapy and the mechanisms
for overcoming resistance in metastatic disease.
Abstract: http://links.ealert.nature.com/ctt?kn=68&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=50&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Intraperitoneal therapy for peritoneal tumors: biophysics and clinical
evidence
Wim P. Ceelen and Michael F. Flessner
Published online: 15 December 2009
p108 | doi:10.1038/nrclinonc.2009.217
It has been established that intraperitoneal drug administration is
advantageous in patients with tumors confined to the peritoneal cavity.
The authors of this Review discuss intraperitoneal drug delivery including
the optimal drug, dose and schedule.
Abstract: http://links.ealert.nature.com/ctt?kn=73&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=60&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
T-cell lymphoproliferative disorder potentially induced by imatinib in
a patient with GIST
Mareike Verbeek, Falko Fend, Thomas Licht, Christian Meyer zum Buschenfelde,
Jens Stollfuss, Christian Peschel and Justus Duyster
p116 | doi:10.1038/nrclinonc.2009.218
A 71-year-old male patient was diagnosed with a KIT-positive gastrointestinal
stromal tumor (GIST). The patient received adjuvant imatinib but developed
several subcutaneous and intra-abdominal tumor lesions after 4 months
of treatment. A T-cell lymphoproliferative disorder was suspected. The
authors discuss the potential of imatinib to induce reversible clonal
T-cell proliferations in patients with GIST who develop new tumor
manifestations that are suspicious for relapse.
Abstract: http://links.ealert.nature.com/ctt?kn=75&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=63&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Interested in inflammation?
Please take a look at these articles published recently in Nature Reviews
Immunology and Nature Reviews Rheumatology:
Transcriptional control of the inflammatory response
Ruslan Medzhitov & Tiffany Horng
Nature Reviews Immunology
http://links.ealert.nature.com/ctt?kn=67&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
Recurrent febrile syndrome-what a rheumatologist needs to know Hal M. Hoffman
& Anna Simon
Nature Reviews Rheumatology
http://links.ealert.nature.com/ctt?kn=59&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=71&m=34594733&r=MTc2NDg2OTc4MQS2&b=2&j=NjY0NDIzMTcS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2010 Nature Publishing Group
=====================================================================
